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Background: The hemoglobin threshold for transfusion of red blood cells in patients with acute gastrointestinal
(GI) bleeding is controversial. We compared the efficacy and safety of a restrictive transfusion strategy with those of
a liberal transfusion strategy.
Methods: Objective: The objective was to prove that the restrictive threshold for red blood cell transfusion in
patients with acute upper GI bleeding (UGIB) was safer and more effective than a liberal transfusion strategy.
Design: A single-center, randomized controlled trial was conducted.
Setting: Patients with GI bleeding were admitted to the de la Santa Creu i Sant Pau hospital in Barcelona, Spain.
Subjects: The subjects were adult intensive care unit patients admitted with high clinical suspicion of UGIB
(hematomemesis, melena, or both). Patients were excluded if they had massive exsanguinating bleeding, acute coronary
syndrome, symptomatic peripheral vascular disease, stroke/transient ischemic attack, transfusion within the previous 90
days, recent trauma or surgery, lower GI bleeding, or a clinical Rockall score of 0 with hemoglobin higher than 12 g/dL.
Intervention: A total of 921 patients with severe acute UGIB were enrolled. Of these, 461 were randomly assigned to a
restrictive strategy (transfusion when the hemoglobin level fell to below 7 g/dL) and 460 to a liberal strategy (transfusion
when the hemoglobin fell to below 9 g/dL). Random assignment was stratified according to the presence or absence of
liver cirrhosis.
Outcomes: The primary outcome was rate of death from any cause within the first 45 days. Secondary outcomes were
further bleeding, defined as hematemesis or melena with hemodynamic instability or hemoglobin decrease of 2 g/dL or
more, and in-hospital complications.
Results: In total, 225 patients assigned to the restrictive strategy (51%) and 65 assigned to the liberal strategy (15%) did
not receive transfusions (P <0.001). The probability of survival at 6 weeks was higher in the restrictive-strategy group
than in the liberal-strategy group (95% versus 91%; hazard ratio (HR) for death with restrictive strategy, 0.55; 95%
confidence interval (CI) 0.33 to 0.92; P = 0.02). Further bleeding occurred in 10% of the patients in the restrictive-strategy
group and in 16% of the patients in the liberal-strategy group (P = 0.01), and adverse events occurred in 40% and 48%,
respectively (P = 0.02). The probability of survival was slightly higher with the restrictive strategy than with the liberal
strategy in the subgroup of patients who had bleeding associated with a peptic ulcer (HR 0.70, 95% CI 0.26 to 1.25) and
was significantly higher in the subgroup of patients with cirrhosis and Child-Pugh class A or B disease (HR 0.30, 95% CI
0.11 to 0.85) but not in those with cirrhosis and Child-Pugh class C disease (HR 1.04, 95% CI 0.45 to 2.37). Within the first
5 days, the portal-pressure gradient increased significantly in patients assigned to the liberal strategy (P = 0.03) but not
in those assigned to the restrictive strategy.
Conclusions: Compared with a liberal transfusion strategy, a restrictive strategy significantly improved outcomes in
patients with acute UGIB.* Correspondence: yendes@upmc.edu
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The annual incidence of hospitalization for acute UGIB
is 1 in 1,000 people in North America, translating to
300,000 admissions yearly [1] and a total annual expend-
iture of $2.5 billion [2]. The mortality from UGIB is
approximately 10% and may reach 35% in patients hos-
pitalized with another medical condition [3].
In the critically ill, a more restrictive strategy has been
used for blood transfusion on the basis of a growing
body of data indicating worse outcomes with red blood
cell transfusions in this population [4,5]. However, the
threshold for blood transfusion in patients with UGIB
has been controversial since hemoglobin values may
underestimate the blood loss. Over the past decade, con-
sensus guidelines suggested using a more conservative
approach based on experimental studies, trials in other
populations, and physiologic data [6,7]. A prospective
observational study in patients with UGIB showed that
blood transfusion in the first 12 hours in patients pre-
senting with hemoglobin of more than 8 g/dL increased
mortality and rebleeding rates in comparison with pa-
tients not receiving blood transfusion in the first 12
hours [8]. A recent Cochrane meta-analysis of random-
ized controlled trials examining red blood cell transfu-
sion for the management of UGIB found only three
trials and showed higher mortality and rebleeding rates
for a liberal transfusion strategy. However, these studies
had design flaws and were underpowered [9].
The Transfusion Strategies for Acute Upper Gastro-
intestinal Bleeding trial [10] is a randomized controlled
trial testing liberal and conservative strategies for patients
with UGIB. The authors hypothesized that a restrictive
threshold for red blood cell transfusion (transfusion when
hemoglobin was below 7 g/dL with a goal of 7 to 9 g/dL)
was safer and more effective than a liberal transfusion
strategy (transfusion when hemoglobin was below 9 g/dL
with a goal of 9 to 11 g/dL). Patients with low mortality
and low risk of rebleeding were excluded by using the
Rockall score, which is based on age, presence or absence
of shock, comorbidities, reason for bleeding, and major
stigmata of recent hemorrhage [11]. The primary end-
point was all-cause mortality rate at 45 days. Secondary
outcomes were rebleeding rate and adverse events. The
random assignment was stratified by the presence or
absence of cirrhosis. Twenty-eight percent in the re-
strictive group and 31% in the liberal group were in
shock upon enrollment. The restrictive-strategy group
had a lower mortality rate than the liberal group (5%
versus 9%, P = 0.02) at 45 days, and the relative-risk
reduction was 45% and the number needed to treat
was 25 patients for the restrictive strategy interven-
tion. In addition, the liberal-strategy group had higher
frequency of rebleeding, interventions (transjugular
intrahepatic portosystemic shunt for variceal bleedingand surgery in non-variceal bleeding), and cardiac and
pulmonary adverse effects.
The study had several strengths. First, it used a random-
ized controlled design and a patient-centered outcome
with an adequate number of patients. The protocol was
well devised for hemoglobin checks and management of
complications. The study also had a few concerns. The
protocol allowed the physicians to transfuse in the pres-
ence of signs and symptoms of anemia in case of a massive
bleed and if a surgical intervention was planned. However,
protocol violations in transfusing blood occurred in both
arms, and more violations occurred in the restrictive
group (9% versus 3%).
Multiple mechanisms have been suggested by previous
animal and physiologic studies to explain the increased
mortality and morbidity with a liberal transfusion strat-
egy [12-14]. These include clot rupture, coagulopathy,
changes in stored red blood cells (the storage lesion),
and immunomodulation. The duration of storage of red
blood cells was similar in the two groups, and the coagu-
lation laboratory test results were also similar in the two
groups [15], suggesting that these pathways may not
solely explain differences in outcomes.
Although this study was conducted only in patients
with UGIB, a similar restrictive approach should be con-
sidered by physicians caring for critically ill patients pre-
senting with other acute bleeding episodes, such as
lower GI bleeding and retroperitoneal bleeding. How-
ever, physicians should be careful about extrapolating
these results to patients with massive bleeding or those
with bleeding and acute coronary syndrome.
Recommendation
A restrictive strategy for blood transfusions should be
used for UGIB. The results of this study reinforce the
growing notion that ‘less is more’ for a blood transfusion
strategy in the critically ill.
Abbreviations
CI: Confidence interval; GI: Gastrointestinal bleeding; HR: Hazard ratio;
UGIB: Upper gastrointestinal bleeding.
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